OncoMatch/Clinical Trials/NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Is NCT07397338 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for advanced solid tumors.
Treatment: Daraxonrasib · Elironrasib · Zoldonrasib · Ivonescimab · Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) · cetuximab (Cohort C2 Only) · Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) · Daraxonrasib (Cohort B1 only) — The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Biomarker criteria
Required: HRAS mutation
Required: KRAS mutation
Required: NRAS mutation
Disease stage
Metastatic disease required
locally advanced or metastatic solid tumor malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — advanced/metastatic
Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration)
Lab requirements
Blood counts
adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Kidney function
adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Liver function
adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Eastern Connecticut Hematology and Oncology Associates · Norwich, Connecticut
- Tennessee Oncology · Nashville, Tennessee
- NEXT Dallas · Irving, Texas
- NEXT Oncology · San Antonio, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07397338 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Does this trial require HRAS?
Yes, HRAS mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify